ngLVA degradation kinetics. by Nicole A. Grieshaber (11175417)

“…Chloramphenicol treated sample showed a decrease of half max intensity 30 mins after treatment.…”

Prevalence and anatomic level of stenosis ≥ 50% in either limb. by O. Stivalet (6890189)

Changes in 50-kHz USV duration (A-D) and amplitude (E-H) in rats with 7 (ABEF) or 14 (CDGH) training days during training (ACEG) and test (BDFH) sessions. by Agnieszka D. Wardak (17941139)

Olaparib reverses the oxLDL-mediated decrease in co-immunoprecipitation of IκBα with RelA or p50. by Khamis Mustafa (17941332)

“…Relative band densities from three independent experiments were analyzed. (A) OxLDL decreased co-immunoprecipitation of IκBα with both RelA and p50, and olaparib reversed the effect of oxLDL on the dissociation of IκBα with RelA and p50. …”

Diarrheal stool output rate overall and by blood type status in the modified intent-to-treat population. by Rahsan Erdem (11726357)

Heat map showing time dependent changes for all genes with a ≥ 2-fold maximal increase or decrease in gene expression (mRNA) in response to single doses of IFN-γ. by Daniel R. Ambruso (12042605)

Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Colon tissue and organoid AJC protein expression is decreased with LD shifting in Per2::Luc mice. by Laura Tran (10924702)

“…<p><b>(A)</b> Immunofluorescent staining of E-cadherin (red) in the colon tissue and organoids of shifted and non-shifted Per2::Luc mice. …”

Spatial exploration patterns of non-tumor bearing mice under different treatment conditions in the Morris Water Maze (MWM). by Robert Botelho (20308297)

SARS-CoV-2 inhibits SG formation and decreases expression of G3BP1. by Stacia M. Dolliver (13822801)

The expression of <i>Wnt1</i> gene was decreased in <i>Bmpr</i> double knockout mutants. by Lihua Qin (494786)

Elevated IDO activity in HD mouse brains is decreased by <i>ex-vivo</i> iron chelation. by David W. Donley (3111198)

“…<p>Mouse pups were supplemented with carbonyl iron from postnatal days 10–17 and then were sacrificed at 14 weeks of age. <b>A.</b> Striatal IDO activity is increased in N171-82Q HD mice and significantly decreased by <i>ex vivo</i> iron (III) chelation (50 μM deferoxamine). …”

<i>RTTN</i>-mutated organoids exhibit decreased proliferation and increased cell death at early stages. by Justine Guguin (9088672)

Lipopolysaccharide (LPS) treatment decreases the density of neurons in the ischemic cortical region after stroke in a microglia-dependent manner. by Eric Yuhsiang Wang (17131666)

Subjects:

Definitions of the features selected [50]. by Yu Zhang (12946)

Data_Sheet_1_rdHSV-CA8 non-opioid analgesic gene therapy decreases somatosensory neuronal excitability by activating Kv7 voltage-gated potassium channels.docx by Munal B. Kandel (18526539)

Insufficient disulfide bond formation results in a decrease in alkaline phosphatase activity and accumulation of the reduced form of DegP in LCFA-utilizing cells. by Kanchan Jaswal (9542107)

“…The band corresponding to AP is shown (Mol. wt. ~50 kDa). <i>(C) Compromised DsbA-DsbB machinery is responsible for the decrease in alkaline phosphatase activity in cells utilizing oleate</i>. …”

Decreased respiratory performance of children and adolescents with myelomeningocele who use a wheelchair – preliminary data by E.J. Martins (7141313)

Acquisition of Mutant scFv With a Higher Affinity against Wild-type, Beta and Delta SARS-CoV-2 using a HEK 293T Antibody Surface Display Library. by Ye Yang (297214)

Prognosis and risk factors of chronic kidney disease progression in patients with diabetic kidney disease and non-diabetic kidney disease: a prospective cohort CKD-ROUTE study by Shengnan Chen (3595319)

“…We found that DKD patients have a higher risk to develop 50% eGFR decline endpoint (HR:2.30, 95%CI [1.48–3.58], <i>p</i> < 0.001) and KRT endpoint (HR:1.64, 95%CI [1.13–2.37], <i>p</i> < 0.05) than NDKD patients. …”